Search - tctmd.com

Displaying 41 - 60 of 301

Sort: Relevancy | Date

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Daily News CRT 2021

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Michael O'Riordan

March 17, 2021

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

Presentation TCT Abstracts Posters 2019

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

Presenter: Shinji Imura

September 29, 2019

Presentation TCT 2019

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Presenter: Andrew Farb

September 28, 2019

Presentation TCT 2019

Late Benefits From BVS: Theory and Evidence

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 46: FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 48 Month Outcomes

Presenter: Alexandre Abizaid

September 25, 2019

Presentation TCT 2019

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

Presenter: Stefan Verheye

September 25, 2019

Presentation

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

April 30, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Opinion Off Script TCT 2018

Off Script: Phantom Hearts and the Elusive Nature of Angina

Kwan S. Lee

October 11, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

Presentation ESC 2018

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Presenter: Robert Byrne

August 29, 2018

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

Advertisement

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Late Benefits From BVS: Theory and Evidence

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 46: FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 48 Month Outcomes

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Off Script: Phantom Hearts and the Elusive Nature of Angina

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content